Your session is about to expire
← Back to Search
HCQ for Coronavirus
Study Summary
This trial is testing whether hydroxychloroquine, an antimalarial drug, can help treat symptoms of the new coronavirus, COVID-19.
- Coronavirus
- Coronavirus Infection
- Infectious Diseases
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 3 trial • 217 Patients • NCT02057250Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are people still being signed up for this experiment?
"According to the listing on clinicaltrials.gov, this particular trial is not currently recruiting patients. The study was originally posted on April 4th, 2020 and updated on November 1st, 2022. Although this research is not seeking candidates at the moment, there are 1937 other trials that are actively recruiting participants."
What illnesses does HCQ show the most promise in treating?
"HCQ is a medication that has approved uses for malaria and other diseases like q fever, rheumatoid arthritis, and sjögren's syndrome."
What possible adverse effects could HCQ have on people?
"HCQ's safety rating is a 2. While there have been Phase 2 trials conducted which support its safety, there is no data currently available to suggest that it is an effective medication."
How many people total have signed up for this clinical trial?
"This particular clinical trial is not recruiting patients at this time, however there are other trials that may be of interest. The most recent update to this study was on November 1st, 2022 and it was originally posted April 4th, 2020. There are 1871 studies actively looking for participants with coronavirus infection and 66 studies for HCQ actively searching for patients."
Share this study with friends
Copy Link
Messenger